Author + information
As a key enzyme in fatty acid metabolism, acyl-CoA synthetase long-chain family member 1(ACSL1) is involved in both anabolic and catabolic pathways, and the disturbance of these pathways is closely related to disorders such as hepatic steatosis, hyperlipidemia, and insulin resistance. In addition, our previous gene chip study in patients with acute myocardial infarction (AMI) suggested that ACSL1 gene had high expression in the peripheral blood cells. We thought that ACSL1 gene may affect the process of the occurrence of AMI. The aim of this study is to determine the expression of ACSL1 gene in the peripheral leukocytes of patients with AMI, and to analyze its clinical significance.
75 AMI patients were randomly selected and set as the AMI group, and 70 healthy people were selected as the control group. The clinical data of all study subjects including age, gender, diagnosis, blood lipid, blood pressure, blood glucose and medicine treatment were recorded. 6ml of venous blood was sampled from both two groups for RNA and protein extraction; Real-time Quantitative PCR and Western Blot were then performed to detect the expression of ACSL1 gene on the transcription and the translation levels using GAPDH and β-actin as the internal reference, respectively.
There were no significant differences between these two groups of patients in gender, age, body weight index (BMI), comorbidities, smoking and drinking history. However, there were significant differences in total cholesterol (TC) (4.92±1.22 versus 4.45±0.93, P=0.040), triglyceride (TG) (2.33±0.52 versus 1.65±0.95, P=0.006), low-density lipoprotein (LDL) (3.32±1.05 versus 2.87±0.78, P=0.017) and high-density lipoprotein (HDL) (0.98±0.29 versus 1.06±0.25, P=0.023) levels. The AMI group exhibited higher TC, TG and LDL levels and lower HDL level. At the mRNA level, the relative expression of ACSL1 used the 2-ΔΔCt method and the results showed that the expression of ACSL1 in the AMI group was higher than the control group, and the relative expression was 2.75 (1.47,5.58), consistent with the results of our previous microarray assay. At the translation level, the results of Western Blot showed no significant difference in the expression of β-actin between the two groups, but the protein expression of ACSL1 in the AMI group was significantly higher than the control group. The relative ACSL1 protein expression of AMI group compared with the control group was 2.09±0.72 (P=0.000).
ACSL1 gene was up regulated in the peripheral leukocytes of AMI patients, and its influence on the lipid metabolism was one of the risk factor leading to AMI. This gene may be used as a marker for screening risk population of AMI, and the morbidity of AMI can be reduced through early identification and intervention.